Abstract
Broad-spectrum reactivator is an oxime which is able to reactivate acetylcholinesterase (AChE) inhibited by many kinds of organophosphate inhibitors of AChE, mainly nerve agents. There are many AChE reactivators (oximes) as suitable candidates for the broad-spectrum reactivator. Among them, oxime HI-6 is considered as number one, and due to its properties, it is recommended by many armies to be introduced as universal antidotal mean. In this study, we wanted to summarize that the designation “broad spectrum” is prerogative. For this purpose, in vivo evaluation of therapeutical dose of HI-6 (39.0 mg/kg) was performed. Soman, cyclosarin and tabun were used as the typical members of nerve agent family. According to the obtained results, oxime HI-6 did not sufficiently reactivate tabun-inhibited AChE. Brain AChE was also only partially protected. Based on these results, it seems that HI-6 in therapeutical dose has effect only in peripheral compartment.
Keywords: HI-6, Tabun, Cyclosarin, Soman, Broad-spectrum, Oxime
Letters in Drug Design & Discovery
Title: Potency of HI-6 to Reactivate Cyclosarin, Soman and Tabun Inhibited Acetylcholinesterase – In Vivo Study
Volume: 7 Issue: 7
Author(s): Jana Zdarova Karasova, Jiri Kassa, Miroslav Pohanka, Kamil Musilek and Kamil Kuca
Affiliation:
Keywords: HI-6, Tabun, Cyclosarin, Soman, Broad-spectrum, Oxime
Abstract: Broad-spectrum reactivator is an oxime which is able to reactivate acetylcholinesterase (AChE) inhibited by many kinds of organophosphate inhibitors of AChE, mainly nerve agents. There are many AChE reactivators (oximes) as suitable candidates for the broad-spectrum reactivator. Among them, oxime HI-6 is considered as number one, and due to its properties, it is recommended by many armies to be introduced as universal antidotal mean. In this study, we wanted to summarize that the designation “broad spectrum” is prerogative. For this purpose, in vivo evaluation of therapeutical dose of HI-6 (39.0 mg/kg) was performed. Soman, cyclosarin and tabun were used as the typical members of nerve agent family. According to the obtained results, oxime HI-6 did not sufficiently reactivate tabun-inhibited AChE. Brain AChE was also only partially protected. Based on these results, it seems that HI-6 in therapeutical dose has effect only in peripheral compartment.
Export Options
About this article
Cite this article as:
Zdarova Karasova Jana, Kassa Jiri, Pohanka Miroslav, Musilek Kamil and Kuca Kamil, Potency of HI-6 to Reactivate Cyclosarin, Soman and Tabun Inhibited Acetylcholinesterase – In Vivo Study, Letters in Drug Design & Discovery 2010; 7 (7) . https://dx.doi.org/10.2174/157018010791526269
DOI https://dx.doi.org/10.2174/157018010791526269 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: GPCR-Targeted Drug Development)
Current Drug Targets Antenatal Depression; its Prevalence of Positive Screen and the Associating Risk Factors Including Labor and Neonatal Outcome
Current Women`s Health Reviews Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Cobalt Catalyzed Carbon Nanotube Growth on Graphitic Paper Supports
Current Nanoscience Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support
Current Pharmaceutical Design Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science Basic Mechanisms of Augmentation of Antidepressant Effects with Thyroid Hormone
Current Drug Targets Cannabis Associated “High” Cardiovascular Morbidity and Mortality: Marijuana Smoke Like Tobacco Smoke? A Déjà Vu/Déjà Vécu Story?
Mini-Reviews in Medicinal Chemistry Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives
Current Cancer Drug Targets Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome
Current Vascular Pharmacology N-Substituted Aryl Sulphonamides as Potential Anti-Alzheimer’s Agents: Design, Synthesis and Biological Evaluation
Current Computer-Aided Drug Design Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment
Current Pharmaceutical Design Current Update on Synopsis of miRNA Dysregulation in Neurological Disorders
CNS & Neurological Disorders - Drug Targets TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets Characterising the Folding Pathways of Topologically Knotted Proteins
Current Physical Chemistry Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic Pain
Current Medicinal Chemistry Adult Neurogenesis and Drug Therapy
Central Nervous System Agents in Medicinal Chemistry COMT Implication in Cognitive and Psychiatric Symptoms in Chromosome 22q11 Microdeletion Syndrome: A Selective Review
CNS & Neurological Disorders - Drug Targets Consequences of Cannabinoid and Monoaminergic System Disruption in a Mouse Model of Autism Spectrum Disorders
Current Neuropharmacology